Apmonia Therapeutics Employee Directory
Biotechnology ResearchGrand Est, France11-50 Employees
Apmonia Therapeutics is a clinical-stage biotechnology company developing peptide-based therapies aimed at modulating the tumor microenvironment in solid cancers. Its work targets the protective ecosystem surrounding tumors that supports growth, immune escape, and treatment resistance. The lead candidate, TAX2, targets the TSP-1/CD47 signaling axis and is advancing to Phase 1/2a in advanced solid tumors after favorable preclinical data and a European regulatory clearance to initiate clinical development. The company is based in Reims, Grand Est, France. In August 2025 it established a dedicated R&D subsidiary in Liège, Belgium, as part of expanding its European footprint, and it strengthened governance with independent board members.